Bone Biologics Corp

Bone Biologics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 16.09, indicating strong short-term liquidity coverage. The company holds total assets of $4.98 million against total liabilities of $0.31 million, resulting in total equity of $4.67 million. Despite this liquidity buffer, the firm reports negative operating cash flow of -$0.80 million for Q1 2026, reflecting ongoing cash burn typical of pre-profitability biotech firms. The market capitalization stands at $2.48 million, trading at a price-to-book ratio of 0.53, suggesting the market values the equity below its book value.

Profitability metrics remain negative, with a return on equity of -16.4% and return on assets of -15.38%. The company reported a net loss of -$0.77 million and an operating loss of -$0.81 million in Q1 2026. These losses contribute to accumulated deficits of approximately $88.9 million since inception, highlighting the extended period of investment required before commercial viability. The absence of revenue generation in the provided snapshot underscores the pre-commercial stage of the business model.

Revenue concentration data is not explicitly detailed in the financial snapshot, but the business model relies heavily on the successful regulatory approval and market acceptance of the NELL-1/DBM product. The company depends on licenses from UCLA TDG for its core technology, creating a single-point-of-failure risk regarding intellectual property rights and milestone payments. Geographic exposure is implied through US-based regulatory filings and potential international manufacturing or clinical partnerships, though specific regional revenue splits are absent.

Growth trajectory is currently defined by capital preservation and clinical progress rather than top-line expansion. The company has incurred consistent losses, with no positive revenue history provided in the snapshot to establish a growth rate. Future growth is contingent upon achieving FDA authorization for NELL-1/DBM and successfully completing clinical trials, which are binary events with significant uncertainty. The lack of operating history limits the ability to project organic revenue growth.

Risk factors are elevated, with filings explicitly referencing going-concern or substantial-doubt language due to accumulated losses and the need for additional capital. Dilution risk is assessed as medium, driven by the presence of warrants, pre-funded warrants, and an ATM agreement that allows for future equity issuance. The company faces regulatory risks related to FDA approval, reliance on third-party manufacturers, and potential product liability claims.

Recent events include an 8-K filing with high severity items related to material agreements and changes in securities, indicating active capital raising or restructuring activities. The company continues to navigate the complexities of clinical development and regulatory compliance, with management emphasizing the uncertainties surrounding future funding and market acceptance.

Operating income -$805.1k.

• ▍Operating income -$805.1k

Operating income -$2.5M.

• ▍Operating income -$2.5M

Operating income -$1.8M.

• ▍Operating income -$1.8M

Operating income -$3.2M.

• ▍Operating income -$3.2M

Operating income -$4.2M.

• ▍Operating income -$4.2M

Operating income -$4.2M.

• ▍Operating income -$4.2M

Operating income -$9.4M.

• ▍Operating income -$9.4M

Operating income -$9.4M.

• ▍Operating income -$9.4M